JP2021530487A - Ｅｐ４阻害剤およびその合成 - Google Patents

Ｅｐ４阻害剤およびその合成 Download PDF

Info

Publication number
JP2021530487A
JP2021530487A JP2021500587A JP2021500587A JP2021530487A JP 2021530487 A JP2021530487 A JP 2021530487A JP 2021500587 A JP2021500587 A JP 2021500587A JP 2021500587 A JP2021500587 A JP 2021500587A JP 2021530487 A JP2021530487 A JP 2021530487A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
cancer
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021500587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530487A5 (enExample
Inventor
マーク マンフレディ，
ジェフリー エクセディ，
アルフレッド シー． カストロ，
祥征 奥村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Askat Inc
Original Assignee
Askat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askat Inc filed Critical Askat Inc
Publication of JP2021530487A publication Critical patent/JP2021530487A/ja
Publication of JP2021530487A5 publication Critical patent/JP2021530487A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/63—N-sulfonylisoureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021500587A 2018-07-11 2019-07-11 Ｅｐ４阻害剤およびその合成 Pending JP2021530487A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862696440P 2018-07-11 2018-07-11
US62/696,440 2018-07-11
US201862737250P 2018-09-27 2018-09-27
US62/737,250 2018-09-27
US201962834525P 2019-04-16 2019-04-16
US62/834,525 2019-04-16
PCT/US2019/041351 WO2020014445A1 (en) 2018-07-11 2019-07-11 Ep4 inhibitors and synthesis thereof

Publications (2)

Publication Number Publication Date
JP2021530487A true JP2021530487A (ja) 2021-11-11
JP2021530487A5 JP2021530487A5 (enExample) 2022-07-20

Family

ID=69141735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500587A Pending JP2021530487A (ja) 2018-07-11 2019-07-11 Ｅｐ４阻害剤およびその合成

Country Status (7)

Country Link
US (2) US20210300921A1 (enExample)
EP (1) EP3820469A4 (enExample)
JP (1) JP2021530487A (enExample)
CN (1) CN113301896A (enExample)
CA (1) CA3107023A1 (enExample)
IL (1) IL280051B2 (enExample)
WO (1) WO2020014445A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
US11254675B2 (en) * 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
CN110386941A (zh) * 2019-08-15 2019-10-29 上海邦耀生物科技有限公司 Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
WO2021205367A1 (en) * 2020-04-08 2021-10-14 Askat Inc. Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia
TWI877433B (zh) * 2020-11-30 2025-03-21 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
WO2022247881A1 (zh) * 2021-05-28 2022-12-01 凯复(苏州)生物医药有限公司 治疗肿瘤的联合疗法
WO2023012820A1 (en) * 2021-08-01 2023-02-09 Zenfold Sustainable Technologies Private Limited A process for the preparation of grapiprant and its intermediates
CN117800905A (zh) * 2022-09-26 2024-04-02 洛阳惠中兽药有限公司 4-(2,6-二甲基-3-硝基吡啶-4-基氨基)苯乙基氨基甲酸苄基酯的制备方法
CN117466888A (zh) * 2023-10-30 2024-01-30 西北农林科技大学 一种1h-咪唑并[4,5-c]吡啶化合物的制备方法
CN121270438B (zh) * 2025-12-09 2026-04-28 荆楚理工学院 一种含磺酰脲结构化合物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006249089A (ja) * 2005-03-11 2006-09-21 Pfizer Inc 結晶形態のイミダゾール誘導体
JP2007504210A (ja) * 2003-09-03 2007-03-01 ファイザー株式会社 プロスタグランジンｅ２拮抗薬としてのフェニルまたはピリジルアミド化合物
JP2007533723A (ja) * 2004-04-20 2007-11-22 ファイザー・プロダクツ・インク α２δリガンドを含む組合せ
JP2016501241A (ja) * 2012-12-06 2016-01-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｅｐ４アンタゴニストとしての新規ベンゾイミダゾール誘導体
JP2017507161A (ja) * 2014-03-06 2017-03-16 アラタナ セラピューティクス、 インコーポレイテッド グラピプラントの結晶型
WO2018084230A1 (en) * 2016-11-04 2018-05-11 Askat Inc. Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
CA2754702C (en) * 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504210A (ja) * 2003-09-03 2007-03-01 ファイザー株式会社 プロスタグランジンｅ２拮抗薬としてのフェニルまたはピリジルアミド化合物
JP2007533723A (ja) * 2004-04-20 2007-11-22 ファイザー・プロダクツ・インク α２δリガンドを含む組合せ
JP2006249089A (ja) * 2005-03-11 2006-09-21 Pfizer Inc 結晶形態のイミダゾール誘導体
JP2016501241A (ja) * 2012-12-06 2016-01-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｅｐ４アンタゴニストとしての新規ベンゾイミダゾール誘導体
JP2017507161A (ja) * 2014-03-06 2017-03-16 アラタナ セラピューティクス、 インコーポレイテッド グラピプラントの結晶型
WO2018084230A1 (en) * 2016-11-04 2018-05-11 Askat Inc. Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
医薬審発第１２１６００１号, JPN6023030362, 2002, ISSN: 0005283793 *

Also Published As

Publication number Publication date
CN113301896A (zh) 2021-08-24
EP3820469A4 (en) 2022-04-13
IL280051B1 (en) 2023-11-01
US20240254120A1 (en) 2024-08-01
IL280051B2 (en) 2024-03-01
EP3820469A1 (en) 2021-05-19
WO2020014445A1 (en) 2020-01-16
US20210300921A1 (en) 2021-09-30
IL280051A (en) 2021-03-01
CA3107023A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
US12577208B2 (en) TEAD inhibitors and uses thereof
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
US20240240255A1 (en) Bicycle conjugates specific for nectin-4 and uses thereof
KR20230172548A (ko) Mek 억제제 및 이의 용도
US12295962B2 (en) Polymorphic compounds and uses thereof
JP2023553866A (ja) Ｔｅａｄ阻害剤、及びその使用
JP2022528887A (ja) バイシクルトキシンコンジュゲートおよびその使用
JP2021535146A (ja) Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法
JP2021522211A (ja) Ｅｐ４阻害剤およびその使用
US12459895B2 (en) MEK inhibitors and uses thereof
WO2023114984A1 (en) Tead inhibitors and uses thereof
WO2023173053A1 (en) Mek inhibitors and uses thereof
JP2022500485A (ja) グラピプラント単位剤形
CA3122644A1 (en) Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2023211889A1 (en) Polymorphic compounds and uses thereof
EA052011B1 (ru) Бициклические конъюгаты, специфические в отношении нектина-4, и варианты их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220711

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240315